Positron emission tomography changes in PARK1 mutation.
Perani
Daniela
D
Garibotto
Valentina
V
Hadjigeorgiou
George M
GM
Papadimitriou
Dimitra
D
Fazio
Ferruccio
F
Papadimitriou
Alexandros
A
D000328:Adult; D001921:Brain / Q000000981:diagnostic imaging; D002250:Carbon Radioisotopes; D002869:Chromosome Aberrations; D003042:Cocaine / Q000031:analogs & derivatives; D004252:DNA Mutational Analysis; D005260:Female; D015870:Gene Expression / Q000502:physiology; D005799:Genes, Dominant; D006580:Genetic Carrier Screening; D006801:Humans; D020961:Lewy Body Disease / Q000000981:diagnostic imaging / Q000235:genetics; D008875:Middle Aged; D009460:Neurologic Examination; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000235:genetics*; D010641:Phenotype; D049268:Positron-Emission Tomography; D020891:Raclopride; D011954:Receptors, Dopamine / Q000235:genetics; D017661:Receptors, Presynaptic / Q000235:genetics; D051844:alpha-Synuclein / Q000235:genetics*
D002250:Carbon Radioisotopes; D011954:Receptors, Dopamine; D017661:Receptors, Presynaptic; C497604:SNCA protein, human; D051844:alpha-Synuclein; D020891:Raclopride; C069723:2beta-carbomethoxy-3beta-(4-iodophenyl)tropane; D003042:Cocaine